so Michele, who is living with PNH, can spend more time riding her beloved horse

Male Apellis employee holding a horse saddle

Supply Chain at Apellis

We are a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing medicines. By pioneering targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.

Learn More
Folded page of a newspaper

Latest news

July 31, 2020

Apellis Pharmaceuticals Reports Second Quarter 2020 Financial Results

July 7, 2020

Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)

July 2, 2020

Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

A man with a baby in a baby carrier

At the heart of our company is the belief that exceptional science and compassion are not mutually exclusive.

Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

We are advancing therapies

for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
C3 glomerulopathy, and cold agglutinin disease.

3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

Our lead investigational products

are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.


we replace impossible with How

so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike

We challenge conventional thinking and always question if there's a better way.

Join Us
Female Apellis employee holding a pug

Quality Assurance at Apellis